Biofrontera Inc.
BFRI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.01 | 0.00 | 0.00 |
| FCF Yield | -36.01% | -45.78% | -93.36% | -16.93% |
| EV / EBITDA | -1.91 | -0.89 | -1.94 | -4.48 |
| Quality | ||||
| ROIC | -198.11% | -565.59% | -75.08% | -16.07% |
| Gross Margin | 72.50% | 73.64% | 64.19% | 58.02% |
| Cash Conversion Ratio | 0.57 | 0.57 | 0.98 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.40% | 10.50% | 11.17% | 9.17% |
| Free Cash Flow Growth | -25.48% | 26.07% | -304.72% | 15.73% |
| Safety | ||||
| Net Debt / EBITDA | -0.23 | 0.45 | -0.80 | 0.88 |
| Interest Coverage | -56.56 | -44.17 | -37.89 | -31.13 |
| Efficiency | ||||
| Inventory Turnover | 0.44 | 0.59 | 0.47 | 0.79 |
| Cash Conversion Cycle | 70.88 | 5.01 | 136.69 | 119.86 |